Immune‐checkpoint inhibitors (ICIs), represented by PD‐1/PD‐L1 inhibitors, are deemed a milestone and have become an indispensable part of the standard regimen for advanced hepatobiliary tumors. Here, PDCD1 is linked to hepatobiliary neoplasm.